OakChart

ICU Medical Inc

ICUIHealthcare·Medical Instruments & Supplies·USA·Mid·NASD·Nov 11 • 9:33 AM ET

176.17-5.94 (-3.26%)
2026-11-11 15:33 CET
Market cap
4,554.59 USD m
Revenue, TTM
2,184.42 USD m
Net income, TTM
60.33 USD m
Free cash flow, TTM
208.60 USD m
EPS diluted, TTM
2.39
P/E
73.74
Compare

Price

ICUI against its 20, 50 and 200-day averages
2050200beat
120.00140.00160.00180.00466K931KMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26ICUIclose 176.1720-day 167.5050-day 163.27200-day 149.30176.17

8.6% under 192.85 on 7 Aug 2026. Last 15 sessions, 16.1% high to low

Profile

ICUI
52-week range, 79% of the way up
113.37192.85

ICU Medical, Inc. engages in the provision of innovative medical products used in infusion therapy and critical care applications. Its product portfolio includes IV smart pumps, sets, connectors, closed system transfer devices for hazardous drugs, sterile IV solutions, cardiac monitoring systems, along with pain management and safety software technology designed to help meet clinical, safety and workflow goals. The company was founded by George A. Lopez in 1984 and is headquartered in San Clemente, CA.

IndexRUT
Employees13000
IPOMar 31, 1992
Beta0.86
ATR, 14d6.90
Rel volume0.34
Short float6.81%
Insider own1.77%
Inst own105.27%

Snapshot

6 groups

Valuation

IndexRUT
Market Cap4.41B
Enterprise Value5.31B
Income60.33M
Sales2.18B
Book/sh87.62
Cash/sh12.07
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout0.00%
Employees13000
IPOMar 31, 1992

Ratios

P/E73.74
Forward P/E18.21
PEG1.72
P/S2.02
P/B2.01
P/C14.60
P/FCF21.12
EV/EBITDA14.00
EV/Sales2.43
Quick Ratio1.14
Current Ratio2.32
Debt/Eq0.55
LT Debt/Eq0.54
Option/ShortYes / Yes

Earnings

EPS (ttm)2.39
EPS next Y9.67
EPS next Q2.16
EPS this Y14.64%
EPS next Y8.75%
EPS next 5Y10.58%
EPS past 3/5Y- -62.61%
Sales past 3/5Y-0.68% 11.90%
EPS Y/Y TTM886.62%
Sales Y/Y TTM-5.82%
EPS Q/Q875.94%
Sales Q/Q4.44%
EarningsNov 05 AMC
EPS/Sales Surpr.14.17% 0.76%

Ownership

Insider Own1.77%
Insider Trans-9.14%
Inst Own105.27%
Inst Trans0.62%
ROA1.50%
ROE2.79%
ROIC1.79%
Gross Margin34.14%
Oper. Margin8.05%
Profit Margin2.76%
SMA205.18%
SMA507.90%
SMA20018.00%
Trades-

Technical

Shs Outstand25.01M
Shs Float24.57M
Short Float6.81%
Short Ratio6.67
Short Interest1.67M
52W High192.85 -8.65%
52W Low113.37 55.39%
Volatility5.68% 3.75%
ATR (14)6.90
RSI (14)58.99
Beta0.86
Rel Volume0.34
Avg Volume250.66K
Volume4,926

Performance

Perf Week2.06%
Perf Month7.93%
Perf Quarter-3.79%
Perf Half Y44.35%
Perf YTD23.48%
Perf Year23.01%
Perf 3Y115.08%
Perf 5Y-27.29%
Perf 10Y22.09%
Recom1.25
Target Price196.57
Prev Close182.11
Price176.17
Change %-3.26%

Analyst ratings

latest 10 of 20
DateActionAnalystRating changeTargetImplied
Jun 15, 2026InitiatedBBTIG ResearchBuy$170-3.5%
May 27, 2026UpgradeNNeedhamHold → Buy$165-6.3%
Aug 15, 2025InitiatedPPiper SandlerOverweight$145-17.7%
Mar 12, 2025UpgradeRRaymond JamesOutperform → Strong Buy$205 → $197+11.8%
Dec 11, 2024UpgradeJJefferiesHold → Buy$200+13.5%
Oct 14, 2024InitiatedJJefferiesHold$183+3.9%
Jun 21, 2024InitiatedNNeedhamHold
Jun 17, 2024UpgradeRRaymond JamesMkt Perform → Outperform$135-23.4%
Nov 08, 2022DowngradeRRaymond JamesOutperform → Mkt Perform
Mar 31, 2020UpgradeCCJS SecuritiesMarket Perform → Market Outperform

Peers

Mkt cap
TickerCompanyMkt cap
BAXBaxter International Inc13.52B
BDXBecton Dickinson & Co57.65B
TFXTeleflex Incorporated6.16B
MMSIMerit Medical Systems Inc5.23B
ANGOAngiodynamic Inc514.33M
KRMDKORU Medical Systems Inc159.76M
UTMDUtah Medical Products Inc208.78M
CAHCardinal Health Inc63.96B
TNDMTandem Diabetes Care Inc1.33B
MDTMedtronic Plc128.54B

Insider trading

latest 14 of 47
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Sanzone Virginia RuthVP, General CounselSep 03 '26Sale168.694,856819,15014,604Sep 03 06:29 PM
VIRGINIA SANZONEOfficerSep 03 '26Proposed Sale168.694,856819,150Sep 03 04:02 PM
Bonnell Brian MichaelChief Financial OfficerSep 01 '26Sale175.006,3811,116,67556,062Sep 01 05:21 PM
BRIAN BONNELLOfficerSep 01 '26Proposed Sale175.006,3811,116,675Sep 01 04:07 PM
Bonnell Brian MichaelChief Financial OfficerAug 31 '26Sale172.799,3071,608,14362,443Aug 31 04:43 PM
BRIAN BONNELLOfficerAug 31 '26Proposed Sale172.799,3071,608,143Aug 31 04:13 PM
Woolson DanielVP, GM-Infusion CapitalAug 13 '26Sale181.335,417982,26517,062Aug 13 06:56 PM
DANIEL WOOLSONOfficerAug 13 '26Proposed Sale181.335,417982,265Aug 13 04:17 PM
Sousa BenChief Information OfficerAug 12 '26Sale178.322,250401,2093,076Aug 12 04:33 PM
BENJAMIN SOUSAOfficerAug 12 '26Proposed Sale178.322,250401,209Aug 12 04:24 PM
Voigtlander Christian B.Chief Operating OfficerAug 11 '26Sale182.938,9291,633,40437,377Aug 11 06:18 PM
FINNEY ELISHA WDirectorAug 11 '26Sale182.4837868,9784,871Aug 11 05:59 PM
CHRISTIAN VOIGTLANDEROfficerAug 11 '26Proposed Sale182.938,9291,633,404Aug 11 04:32 PM
ELISHA W FINNEYDirectorAug 11 '26Proposed Sale182.4837868,978Aug 11 04:11 PM

Held by

AUM
TickerCompanyAUM
IJRiShares Core S&P Small-Cap ETFAUM: 106.27B
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
IWMiShares Russell 2000 Index FundAUM: 77.38B
VBVanguard Morningstar Small-Cap ETFAUM: 79.59B
DFSVUS Small Cap Value Portfolio ETF Class Shares-
VBRVanguard Morningstar Small-Cap Value ETFAUM: 37.76B
VXFVanguard Extended Market Index ETFAUM: 30.47B
IWNiShares Russell 2000 Value ETFAUM: 14.10B
SPSMState Street SPDR Portfolio S&P 600TM Small Cap ETFAUM: 16.06B
DFASU.S. Small Cap Portfolio-ETF Class Shares-

News

latest 14 of 206
  • ICU Medical to Present at the 2026 Jefferies Global Healthcare Conference in London (GlobeNewswire)
  • ICU Medical Beats On Record Infusion Systems Sales, But Pulled-Forward Volume And 2027 Cost Pressures Limit The Upside (Earnings Whispers)
  • ICU Medical: Q3 Earnings Snapshot (Associated Press)
  • ICU Medical Announces Third Quarter 2026 Results and Reaffirms Fiscal Year 2026 Guidance, Expecting Results at the High End of Range (GlobeNewswire)
  • ICU Medical's Raised Outlook Faces A Skeptical Market As Pump Momentum Gets Tested (Earnings Whispers)
  • Loading…
  • ICU Medical Announces Time of Third Quarter 2026 Earnings Conference Call (GlobeNewswire)
  • ICU Medical to Participate in Upcoming Investor Conferences (GlobeNewswire)
  • ICU Medical Inc (ICUI) (Q2 2026) Earnings Call Highlights: Strong Organic Growth and Raised ... (GuruFocus.com) +10.93%
  • ICU Medical: Q2 Earnings Snapshot (Associated Press)
  • ICU Medical Announces Second Quarter 2026 Results and Updates its Fiscal Year 2026 Guidance (GlobeNewswire)
  • ICU Medical Announces Time of Second Quarter 2026 Earnings Conference Call (GlobeNewswire)
  • Otsuka ICU Medical outlays $500m to expand US manufacturing footprint (Medical Device Network)
  • Otsuka ICU Medical LLC Announces Over $500M Expansion of IV Solutions Manufacturing in North America (PR Newswire)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-11-052.4402.1371.070556.22552.037
2026Q22026-08-062.3701.9140.762547.88533.447
2026Q12026-05-071.9701.7521.197525.77520.656
2025Q42026-02-191.9101.693-0.637535.94530.586
2025Q32025-11-062.0301.434-0.138533.3508.856
2025Q22025-08-072.1001.5011.430543.57540.085
2025Q12025-05-081.7201.280-0.631599.49570.125
2024Q42025-02-272.1101.482-0.973621.62596.645
2024Q32024-11-121.5901.250-1.350580.07574.66
2024Q22024-08-071.5600.998-0.878581556.645
2024Q12024-05-070.9600.820-1.630566.7552.254
2023Q42024-02-271.5701.193-0.710575.74562.984
2023Q32023-11-061.5701.3850.297546.62565.752
2023Q22023-08-071.8801.600-0.413535.11565.23
2023Q12023-05-081.7401.427-0.409555.9561.133
2022Q42023-02-271.6001.560-0.648564.89578.773

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2019FY8.1507.8574.6901,1881,187
2020FY7.1306.7934.0231,2161,202
2021FY7.3907.2104.7351,2741,264
2022FY6.5406.503-3.1122,2262,240
2023FY6.7606.390-1.2312,2132,201
2024FY6.2205.608-4.8262,3492,318
2025FY7.7607.5720.0302,2122,206
2026FY-8.896--2,188
2027FY-9.674--2,278
2028FY-10.494--2,372
2029FY-10.500--2,309
2030FY-11.090--2,364

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-11-06702558.7554.8566.6
2026Q4S2026-11-05700560.96554.8569.4
2026Q4S2026-10-09700560.96554.8569.4
2026Q4S2026-08-07700561.03554.8569.4
2026Q4S2026-07-13700561.09555.9566.6
2026Q4S2026-07-10700561.14555.9566.6
2026Q4S2026-06-12700560.93555.51566.6
2026Q4S2026-05-08600561.83555.9566.6
2026Q4S2026-05-06600562.27558.3571.1
2026Q4S2026-04-16630562.27558.3571.1
2026Q4S2026-02-27630562.25558.3571
2026Q4S2026-02-20630562.18558.3571
2026Q4S2026-02-02300543.47530550.9
2026Q4S2025-11-11200539.75530549.5

Estimate history

EPS, annual3.2911.3334.694.0234.735-3.112-1.231-4.8260.0292.3891
Period201720182019202020212022202320242025TTM
EPS, quarterly-1.35-0.973-0.6311.43-0.138-0.6371.1970.7621.068
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual1292.6131400.041266.2081271.0041316.3082276.1682258.832379.0652230.0252184.42
Period201720182019202020212022202320242025TTM
Sales, quarterly588.391628.897603.993548.702537.712540.261530.374552.189561.592
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual20.2120.49120.74221.05821.2823.99524.14124.51724.68825.01
Period201720182019202020212022202320242025MRQ
Shares, quarterly24.45924.51724.61124.68524.68624.68824.99325.00725.01
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue2,184.422,230.032,379.072,258.832,276.171,316.311,271.001,266.211,400.04
Cost of Goods Sold Incl. D&A1,438.591,544.411,557.361,527.111,613.64837.86810.30795.26830.75
Gross Profit745.83685.61821.71731.73662.53478.45460.71470.95569.28
Selling, General and Administrative Excl. Other570.07578.66727.38692.04677.68340.49326.90325.59373.11
Research and Development86.8287.5088.6185.3492.9847.5042.9548.6152.87
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income175.76106.9594.3339.69-15.15137.97133.81145.35196.17
Interest Expense83.53105.38133.85135.3177.760.981.750.550.71
Unusual Expense67.6666.5054.4425.0139.3318.1636.4338.91167.40
Net Income Before Taxes39.454.36-66.01-78.30-114.41123.1997.49114.7122.37
Income Taxes-23.102.4451.68-48.64-40.1220.0510.6213.67-6.42
Consolidated Net Income60.330.73-117.69-29.66-74.29103.1486.87101.0328.79
Net Income From Continuing Operations60.330.73-117.69-29.66-74.29103.1486.87101.0328.79
Net Income60.330.73-117.69-29.66-74.29103.1486.87101.0328.79
EPS (Recurring)4.281.90-3.26-0.50-1.965.325.205.956.76
EPS (Basic, Before Extraordinaries)2.420.03-4.83-1.23-3.114.864.164.901.41
EPS (Diluted)2.390.03-4.83-1.23-3.114.744.024.691.33
EBITDA379.34324.94335.19290.37243.65237.26228.65230.56270.91
Non-Operating Income (Expense)14.8769.2927.9542.3317.824.371.888.81-5.69
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense40.7849.8641.3635.1831.3920.9518.3917.0818.54
Price To Earnings Ratio76.2376.23---50.0053.2239.81174.13
Price To Sales Ratio1.851.591.591.061.653.933.643.183.54
Gross Margin34.1430.7434.5432.3929.1136.3536.2537.1940.66
Operating Margin8.054.803.971.76-0.6710.4810.5311.4814.01
Net Margin2.760.03-4.95-1.31-3.267.846.837.982.06
Shares Outstanding25.0124.6924.5224.1424.0021.2821.0620.7420.49
Market Capitalization4,554.594,554.593,799.232,407.733,776.625,040.894,500.243,868.334,704.89

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q4
Total Revenue561.59552.19530.37540.26537.71548.70603.99628.90
Cost of Goods Sold Incl. D&A358.79349.34357.28373.18335.39340.41393.58404.13
Gross Profit202.80202.85173.10167.08202.32208.29210.41224.76
Selling, General and Administrative Excl. Other142.97141.41142.42143.27174.02181.26180.52181.20
Research and Development21.7522.7021.2821.0921.2521.8723.2922.36
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income59.8361.4430.6823.8128.3027.0329.8943.56
Interest Expense19.2519.6919.7524.8425.1426.3829.0231.23
Unusual Expense9.1021.3016.8020.4513.1416.2216.708.36
Net Income Before Taxes36.1823.14-3.98-15.90-2.5133.68-10.918.22
Income Taxes7.197.07-34.71-2.65-0.661.184.5732.05
Consolidated Net Income26.8519.0930.13-15.73-3.4035.34-15.48-23.83
Net Income From Continuing Operations26.8519.0930.13-15.73-3.4035.34-15.48-23.83
Net Income26.8519.0930.13-15.73-3.4035.34-15.48-23.83
EPS (Recurring)1.321.361.66-0.060.231.89-0.15-0.73
EPS (Basic, Before Extraordinaries)1.070.761.22-0.64-0.141.43-0.63-0.97
EPS (Diluted)1.070.761.20-0.64-0.141.43-0.63-0.97
EBITDA109.43111.0580.7078.1579.1076.7079.3396.55
Non-Operating Income (Expense)4.702.701.905.577.4749.244.924.25
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense9.379.3811.0710.9612.0411.429.6214.21
Price To Earnings Ratio76.2379.165,250.00-----
Price To Sales Ratio1.851.701.511.581.281.381.411.60
Gross Margin36.1136.7432.6430.9337.6337.9634.8435.74
Operating Margin10.6511.135.784.415.264.934.956.93
Net Margin4.783.465.68-2.91-0.636.44-2.56-3.79
Shares Outstanding25.0125.0124.9924.6924.6924.6824.6124.52
Market Capitalization4,554.593,664.063,188.753,522.052,961.303,252.463,404.713,799.23

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments307.96308.57254.72213.01567.25410.78292.64382.11300.13
Short Term Receivables180.51187.27164.31225.26110.05127.77206.64196.44211.50
Inventories615.86584.68709.36696.01290.24314.93337.64311.16288.66
Other Current Assets73.11352.4191.2198.5249.5360.8941.9535.3864.37
Total Current Assets1,177.441,432.921,219.601,232.801,017.06914.38878.87925.09864.66
Net Property, Plant & Equipment511.89499.30685.52710.98508.21513.20490.55432.64398.68
Total Investments and Advances132.328.768.6730.547.8612.970.002.5714.58
Long-Term Note Receivable-23.6330.6327.0925.94----
Intangible Assets2,133.312,173.562,343.032,432.02231.75230.23242.65144.62156.11
Deferred Tax Assets25.8924.2137.3031.4742.6031.0328.0038.6524.77
Other Assets69.6541.5453.6950.7547.3161.8852.3241.8338.14
Total Assets4,050.514,203.934,378.444,515.641,880.741,763.691,692.381,585.391,496.95
Short Term Debt Incl. Current Port. of LT Debt34.6767.7672.0248.679.659.297.360.000.00
Accounts Payable154.37148.02150.03215.9081.1371.86128.63120.4778.23
Income Tax Payable10.4017.337.7112.043.432.454.682.94-
Other Current Liabilities299.42323.07252.07217.94106.56111.88107.80125.88132.06
Total Current Liabilities498.86556.18481.84494.56200.78195.49248.47249.29210.29
Long Term Debt1,313.601,574.971,632.701,686.4536.0443.4128.900.000.00
Provision for Risks Charges0.006.4026.0625.290.000.000.000.0027.00
Deferred Tax Liabilities37.7648.8155.87126.011.491.662.090.721.49
Other Liabilities76.4752.3358.5793.4126.4020.8735.6871.7359.92
Total Liabilities1,926.682,238.702,255.032,425.71264.71261.43315.14321.74298.70
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.000.00
Common Equity2,123.821,965.232,123.412,089.931,616.031,502.271,377.241,263.651,198.25
Total Shareholders Equity2,123.821,965.232,123.412,089.931,616.031,502.271,377.241,263.651,198.25
Accumulated Minority Interest0.000.000.000.000.000.000.000.000.00
Total Equity2,123.821,965.232,123.412,089.931,616.031,502.271,377.241,263.651,198.25
Total Liabilities & Stockholders Equity4,050.514,203.934,378.444,515.641,880.741,763.691,692.381,585.391,496.95
Book Value Per Share86.0380.1687.9687.1075.9471.3466.4061.6759.29
Tangible Book Value Per Share-0.38-8.50-9.10-14.2665.0560.4154.7054.6151.57
Full-Time Employees13,00015,00014,00014,5008,5007,9008,0008,1006,802
Price to Book Ratio2.081.851.151.883.133.012.823.723.79
Return on Assets0.02-2.74-0.67-2.325.665.036.161.876.24
Return on Equity0.04-5.76-1.41-4.016.616.037.652.347.39
Return on Invested Capital0.02-3.32-0.79-1.976.245.627.192.285.73
Quick Ratio1.131.531.061.093.623.072.182.462.74
Current Ratio2.362.582.532.495.074.683.543.714.11

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income60.330.73-117.69-29.66-74.29103.1486.87101.0328.79
Depreciation217.31217.99240.86250.68258.8099.2994.8585.2174.73
Other Funds (Non Cash)86.6251.1783.4380.7857.0850.0758.0027.3182.09
Funds from Operations364.27269.89206.60301.80241.60252.50239.72213.55185.62
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital-85.02-90.04-2.57-135.60-303.7315.04-16.97-111.64-25.41
Cash from Operating Activities279.24179.85204.03166.20-62.13267.54222.75101.92160.22
Capital Expenditures-77.65-97.02-90.21-93.67-99.33-81.17-100.39-106.04-100.78
Net Assets From Acquisitions0.000.000.000.00-1,844.16-14.450.00-76.13-1.30
Sale of Fixed Assets and Businesses225.17219.240.751.500.990.226.180.0313.77
Purchase or Sale of Investments0.000.000.504.2233.044.72-3.9215.25-15.06
Purchase of Investments0.000.000.000.00-3.40-13.28-32.83-26.04-30.50
Sale Or Maturity of Investments0.000.000.504.2236.4318.0028.9041.2915.44
Other Uses0.000.000.000.000.000.000.000.000.00
Other Sources-0.000.000.000.000.000.000.000.00
Cash from Investing Activities-63.66122.23-88.96-87.95-1,909.47-90.69-98.14-166.89-103.37
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock-8.14-2.66-1.05-5.33-2.101.040.32-10.918.02
Repurchase of Common Pref Stock-8.77-8.77-11.99-9.35-10.88-8.34-12.88-18.64-6.25
Sale of Common Pref Stock0.626.1110.944.028.799.3713.197.7314.28
Proceedsfrom Stock Options0.000.000.000.000.000.000.000.000.00
Issuance or Reduction of Debt, Net-171.23-308.87-52.15-30.651,639.13-0.61-0.360.000.00
Change in Long Term Debt-171.23-308.87-52.15-30.651,639.13-0.61-0.360.000.00
Issuance of Long Term Debt-2.51-2.510.000.001,662.180.000.000.000.00
Reduction of Long Term Debt-168.71-306.35-52.15-30.65-23.05-0.61-0.360.000.00
Net Financing Active Other Cash Flow-30.450.00-2.600.000.00-17.300.000.000.00
Other Financing Activities Uses-30.450.00-2.600.000.00-17.300.000.000.00
Cash from Financing Activities-209.81-311.52-55.80-35.981,637.03-16.87-0.04-10.918.02
Exchange Rate Effect-3.728.85-4.933.16-9.48-3.252.85-0.23-10.16
Net Change in Cash2.05-0.6054.3445.44-344.04156.73127.43-76.1154.71
Free Cash Flow208.6091.80124.6682.31-152.44199.00130.754.6167.50
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.000.00
Price to Free Cash Flow19.3538.7030.3629.19-25.9835.42875.2773.49
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments301.78298.30288.33307.96299.73300.02
Short Term Receivables217.71202.39201.08180.51191.54189.53
Inventories607.27607.42605.59615.86622.44616.47
Other Current Assets66.7881.3493.9873.1182.0974.09
Total Current Assets1,193.531,189.451,188.981,177.441,195.801,180.12
Net Property, Plant & Equipment489.51491.26502.13511.89518.37515.70
Total Investments and Advances137.29136.42131.68132.32134.11131.62
Intangible Assets2,019.252,052.052,084.532,133.312,163.592,199.93
Deferred Tax Assets25.4425.5725.6525.8923.9823.07
Other Assets78.7876.5480.7969.6567.0456.95
Total Assets3,943.803,971.284,013.764,050.514,102.904,107.39
Short Term Debt Incl. Current Port. of LT Debt34.2234.3334.1934.6715.5814.74
Accounts Payable142.99149.16173.98154.37171.75168.82
Income Tax Payable10.097.9610.6010.405.040.16
Other Current Liabilities327.33306.91299.13299.42300.53299.06
Total Current Liabilities514.63498.36517.90498.86492.90482.78
Long Term Debt1,172.961,252.821,307.051,313.601,364.541,390.21
Provision for Risks Charges0.000.000.000.000.000.00
Deferred Tax Liabilities8.7612.2314.5137.7641.3743.22
Other Liabilities56.0256.0262.3776.4776.8375.40
Total Liabilities1,752.381,819.431,901.841,926.681,975.651,991.61
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity2,191.422,151.852,111.932,123.822,127.252,115.78
Total Shareholders Equity2,191.422,151.852,111.932,123.822,127.252,115.78
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity2,191.422,151.852,111.932,123.822,127.252,115.78
Total Liabilities & Stockholders Equity3,943.803,971.284,013.764,050.514,102.904,107.39
Book Value Per Share87.6286.0584.5086.0386.1785.71
Tangible Book Value Per Share6.883.991.10-0.38-1.47-3.41
Full-Time Employees---13,000--
Price to Book Ratio2.081.731.501.661.401.64
Return on Assets1.500.741.130.02-0.18-0.88
Return on Equity2.791.412.260.04-0.35-1.78
Return on Invested Capital0.800.560.88-0.46-0.101.01
Quick Ratio1.141.171.131.131.161.17
Current Ratio2.322.392.302.362.432.44

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income26.8519.0930.13-15.73-3.4035.34
Depreciation49.5949.6150.0368.0850.8049.66
Other Funds (Non Cash)22.8925.9522.6915.1031.51-24.71
Funds from Operations99.3394.65102.8567.4478.9260.30
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital0.26-14.50-63.94-6.84-22.21-49.08
Cash from Operating Activities99.5980.1538.9160.6056.7111.21
Capital Expenditures-17.88-20.16-13.21-26.41-31.75-22.00
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses5.950.020.00219.200.000.00
Purchase or Sale of Investments0.000.000.000.000.000.00
Purchase of Investments0.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.00
Other Sources-0.002.00-211.191.72209.46
Cash from Investing Activities-13.93-20.14-11.21-18.39-30.03187.46
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock0.000.490.00-8.630.005.84
Repurchase of Common Pref Stock0.000.000.00-8.770.000.00
Sale of Common Pref Stock0.000.490.000.130.005.84
Proceedsfrom Stock Options0.000.000.000.000.000.00
Issuance or Reduction of Debt, Net-80.67-50.64-5.35-34.57-25.66-200.56
Change in Long Term Debt-80.67-50.64-5.35-34.57-25.66-200.56
Issuance of Long Term Debt0.000.000.00-2.510.000.00
Reduction of Long Term Debt-80.67-50.64-5.35-32.06-25.66-200.56
Net Financing Active Other Cash Flow-0.30-0.09-38.788.72-0.03-0.30
Other Financing Activities Uses-0.30-0.09-38.788.72-0.03-0.30
Cash from Financing Activities-80.97-50.23-44.12-34.48-25.69-195.01
Exchange Rate Effect-1.200.19-3.210.51-1.296.67
Net Change in Cash3.489.97-19.638.23-0.2910.32
Free Cash Flow83.4061.6427.6135.9527.63-8.48
Price to Free Cash Flow19.3524.0239.3238.3741.1553.95

Revenue breakdown

Infusion Consumables2024: 1.04B 2025: 1.11B
Infusion Systems2024: 652.41M 2025: 684.21M
Vital Care2024: 690.77M 2025: 437.92M
APAC2024: 232.82M 2025: 232.90M
EMEA2024: 393.53M 2025: 411.68M
Other foreign countries2024: 223.59M 2025: 230.56M
United States2024: 1.53B 2025: 1.36B

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-306.81%1.7M24.6M261.11K
2026-10-156.97%1.7M24.6M273.19K
2026-09-306.20%1.5M24.6M282.43K
2026-09-156.17%1.5M24.6M296.42K
2026-08-315.84%1.4M24.6M298.74K
2026-08-145.64%1.4M24.5M319.19K
2026-07-315.66%1.4M24.5M303.30K
2026-07-157.47%1.8M24.5M301.39K
2026-06-306.88%1.7M24.5M295.53K
2026-06-157.24%1.8M24.5M287.32K
2026-05-297.50%1.8M24.5M291.83K
2026-05-156.66%1.6M24.5M294.80K
2026-04-306.64%1.6M24.5M289.99K
2026-04-155.31%1.3M24.5M287.30K
2026-03-315.35%1.3M24.4M283.57K
2026-03-134.89%1.2M24.4M263.47K
2026-02-274.61%1.1M24.4M249.92K
2026-02-134.17%1.0M24.4M237.57K
2026-01-304.77%1.1M23.9M255.68K
2026-01-154.80%1.1M23.9M250.84K

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call65.000.000.000.00-0.000.00---
call70.000.000.000.00-0.000.00---
call75.000.000.000.00-0.000.00---
call80.000.000.000.00-0.000.00---
call85.000.000.000.00-0.000.00---
call90.000.000.0036.18-1.000.00---
call95.000.000.000.00-0.000.00---
call1000.000.0027.44-1.000.00---
call1050.000.0027.85-1,5060.00---
call1100.000.0027.00-1,5060.00---
call1150.000.0020.60-7.000.00---
call1200.000.0018.45-3.000.00---
call1250.000.0014.27-14.000.00---
call1300.000.0020.15-1.000.00---
call1350.000.000.00-0.000.00---
call1400.000.0018.90-6.000.00---
call1450.000.0012.40-4.000.00---
call1500.000.000.00-0.000.00---
call1550.000.000.00-0.000.00---
call1600.000.009.80-1.000.00---
call1650.000.008.18-16.000.00---
call1700.000.007.05-28.000.00---
call1750.000.004.74-4.000.00---
call1800.000.000.00-0.000.00---
call1850.000.002.00-10.000.00---
call1900.000.001.00-11.000.00---
call1950.000.000.00-0.000.00---
call2000.000.000.00-0.000.00---
call2100.000.000.00-0.000.00---
call2200.000.000.00-0.000.00---
call2300.000.000.00-0.000.00---
call2400.000.000.00-0.000.00---
call2500.000.000.00-0.000.00---
call2600.000.000.00-0.000.00---
put65.000.000.000.00-0.000.00---
put70.000.000.000.00-0.000.00---
put75.000.000.000.00-0.000.00---
put80.000.000.001.04-0.000.00---
put85.000.000.001.12-0.000.00---
put90.000.000.000.00-0.000.00---
put95.000.000.001.45-1.000.00---
put1000.000.001.30-10.000.00---
put1050.000.000.00-0.000.00---
put1100.000.000.00-0.000.00---
put1150.000.000.00-0.000.00---
put1200.000.003.00-22.000.00---
put1250.000.000.90-11.000.00---
put1300.000.001.15-1.000.00---
put1350.000.001.23-1.000.00---
put1400.000.001.38-4.000.00---
put1450.000.002.40-5.000.00---
put1500.000.002.38-8.000.00---
put1550.000.000.00-0.000.00---
put1600.000.006.70-1.000.00---
put1650.000.009.77-1.000.00---
put1700.000.008.90-1.000.00---
put1750.000.0011.80-1.000.00---
put1800.000.0012.10-2.000.00---
put1850.000.000.00-0.000.00---
put1900.000.000.00-0.000.00---
put1950.000.000.00-0.000.00---
put2000.000.000.00-0.000.00---
put2100.000.000.00-0.000.00---
put2200.000.000.00-0.000.00---
put2300.000.000.00-0.000.00---
put2400.000.000.00-0.000.00---
put2500.000.000.00-0.000.00---
put2600.000.000.00-0.000.00---

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-0510-QQuarterly report pursuant to Section 13 or 15(d)2026-09-30SEC
2026-11-058-KCurrent report2026-11-05SEC
2026-09-03144Filing for proposed sale of securities under Rule 144.SEC
2026-09-034Statement of changes in beneficial ownership of securities2026-09-03SEC
2026-09-01144Filing for proposed sale of securities under Rule 144.SEC
2026-09-014Statement of changes in beneficial ownership of securities2026-09-01SEC
2026-08-31144Filing for proposed sale of securities under Rule 144.SEC
2026-08-314Statement of changes in beneficial ownership of securities2026-08-31SEC
2026-08-14SCHEDULE 13G/ASEC
2026-08-13144Filing for proposed sale of securities under Rule 144.SEC
2026-08-134Statement of changes in beneficial ownership of securities2026-08-13SEC
2026-08-13SCHEDULE 13G/ASEC
2026-08-124Statement of changes in beneficial ownership of securities2026-08-12SEC
2026-08-12144Filing for proposed sale of securities under Rule 144.SEC
2026-08-11144Filing for proposed sale of securities under Rule 144.SEC
2026-08-11144Filing for proposed sale of securities under Rule 144.SEC
2026-08-114Statement of changes in beneficial ownership of securities2026-08-11SEC
2026-08-114Statement of changes in beneficial ownership of securities2026-08-11SEC
2026-08-0610-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-068-KCurrent report2026-08-06SEC
2026-06-01SDSpecialized Disclosure ReportSEC
2026-05-22144Filing for proposed sale of securities under Rule 144.SEC
2026-05-224Statement of changes in beneficial ownership of securities2026-05-22SEC
2026-05-188-KCurrent report2026-05-13SEC
2026-05-154Statement of changes in beneficial ownership of securities2026-05-14SEC
2026-05-14144Filing for proposed sale of securities under Rule 144.SEC
2026-05-13SCHEDULE 13G/ASEC
2026-05-134Statement of changes in beneficial ownership of securities2026-05-13SEC
2026-05-134Statement of changes in beneficial ownership of securities2026-05-13SEC
2026-05-134Statement of changes in beneficial ownership of securities2026-05-13SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-09001.94M2
2026-08004.69M5
2026-070000
2026-060000
2026-0500882.24K3
2026-040000
2026-030000
2026-020000
2026-010000
2025-120000
2025-1100754.18K3

Institutional holders

Manager% owned
BlackRock, Inc.15.02%
Jupiter Topco LLC11.13%
VANGUARD PORTFOLIO MANAGEMENT LLC5.88%
FULLER & THALER ASSET MANAGEMENT, INC.5.19%
VANGUARD CAPITAL MANAGEMENT LLC4.49%
DIMENSIONAL FUND ADVISORS LP4.38%
STATE STREET CORP4.10%
SCHRODER INVESTMENT MANAGEMENT GROUP2.96%
AMERIPRISE FINANCIAL INC2.76%
GEODE CAPITAL MANAGEMENT, LLC2.63%

Funds

Fund% owned
NYLIM Floating Rate Fund10.27%
NYLIM VP Floating Rate Portfolio8.74%
Nuveen Core Plus Bond Fund7.10%
Nuveen Core Bond Fund7.10%
iShares Core S&P Small-Cap ETF6.02%
Janus Henderson Enterprise Fund4.92%
Undiscovered Managers Behavioral Value Fund4.22%
VANGUARD TOTAL STOCK MARKET INDEX FUND3.17%
iShares Russell 2000 ETF2.54%
VANGUARD SMALL-CAP INDEX FUND2.29%

OakChart. ICUI. Cached 15 minutes.